Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 5/20 | 0.67 |
| ▸ | SCD | O00767 | 4/20 | 0.64 |
| ▸ | NAAA | Q02083 | 2/20 | 0.62 |
| ▸ | MAPT | P10636 | 4/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.62 |
| ▸ | LMNA | P02545 | 3/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.62 |
| ▸ | HTT | P42858 | 2/20 | 0.62 |
| ▸ | RAB9A | P51151 | 4/20 | 0.61 |
| ▸ | TP53 | P04637 | 1/20 | 0.58 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.56 |
| ▸ | TSHR | P16473 | 2/20 | 0.56 |
| ▸ | CASP1 | P29466 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | RBP4 | P02753 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4252683 | 0.81 | SCD (0.55) | SCD | |
| SCHEMBL2200579 | 0.81 | MAPT (0.74) | NPC1NAAAMAPTSMN1; SMN2LMNA | |
| SCHEMBL5110011 | 0.80 | SCD (0.76) | SCD | |
| SCHEMBL26829036 | 0.79 | NAAA (0.80) | NPC1NAAAMAPTSMN1; SMN2LMNA | |
| SCHEMBL25083 | 0.78 | SCD (0.66) | SCD | |
| SCHEMBL4092883 | 0.78 | SCD (0.78) | SCD | |
| SCHEMBL4097089 | 0.78 | SCD (1.00) | SCDRBP4 | |
| SCHEMBL25626 | 0.77 | SCD (0.69) | SCD | |
| SCHEMBL25775 | 0.77 | SCD (1.00) | SCD | |
| SCHEMBL19617803 | 0.77 | NAAA (1.00) | NPC1NAAAMAPTSMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090099200-A1 | Azacyclohexane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase | MERCK FROSST CANADA LTD. (CA) | 2009-04-16 | — | — | US | disclosed |
| US-20090099200-A1 | Azacyclohexane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase | MERCK FROSST CANADA LTD. (CA) | 2009-04-16 | — | — | US | disclosed |
| US-20090099200-A1 | Azacyclohexane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase | MERCK FROSST CANADA LTD. (CA) | 2009-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099200-A1 | Azacyclohexane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase | SCD, SCD5, SREBF1 | NPC1 452/4885SCD 1/4885NAAA 541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.